Year : 2015 | Volume
: 57 | Issue : 3 | Page : 326--328
Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen)
Kamala Deka1, Neha Dua1, Monali Kakoty1, Rina Ahmed2,
1 Department of Psychiatry, Assam Medical College and Hospital, Dibrugarh, Assam, India
2 Department of Obstetrics and Gynaecology, Assam Medical College and Hospital, Dibrugarh, Assam, India
Department of Psychiatry, Assam Medical College and Hospital, Dibrugarh, Assam
|How to cite this article:|
Deka K, Dua N, Kakoty M, Ahmed R. Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen).Indian J Psychiatry 2015;57:326-328
|How to cite this URL:|
Deka K, Dua N, Kakoty M, Ahmed R. Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen). Indian J Psychiatry [serial online] 2015 [cited 2021 Oct 22 ];57:326-328
Available from: https://www.indianjpsychiatry.org/text.asp?2015/57/3/326/166633
Persistent genital arousal disorder (PGAD) or restless genital syndrome results in spontaneous, persistent and uncontrollable genital arousal, with or without orgasm or genital engorgement, unrelated to any feelings of sexual desire., Here, we present a case of a 53-year-old female, who is a widow for 25 years. She came to us with 2½ years history of increased sexual sensation in the genital area which she could not control, along with headache, dizziness, low mood, disturbed sleep, and crying spells. She had no desire to have sex, but she used to feel warm inside her vagina with pulsations, lubrication, tingling, throbbing response, and sometimes discharge. Initially, it was 15−20 times a day gradually increased to persist throughout the day. She lied on bed whole day crying, clinging herself or folding her body on herself because of the sensations. To get the relief she used to splash water or sometimes put her fingers inside her vagina following that she felt relief for few minutes but again felt the same sexual sensation. She did not have intercourse, neither did she use any artificial objects for pleasure. Her mood was low throughout the day, sleep disturbed, and appetite decreased. She was a widow for 25 years. No major psychosocial stressor was elicited. There was no history of sexual abuse in childhood. She had attained menopause 4 years back. History of earlier treatment with various such as like conjugated estrogen, cabergoline, alprazolam, vertin, cinnarizine, zolpidem, chlordiazepoxide, escitalopram, clonazepam, clomipramine, and etizolaam in adequate dosages for adequate duration did not have any beneficial effect on her.
After being admitted she was investigated for sexual dysfunction. There was no local genital pathology and per vaginum examination was normal. Investigations like blood sugar levels, kidney function test, liver function test, thyroid profile, blood and urine routine and urine culture were within normal limit. Follicle-stimulating hormone (FSH) levels were raised, prolactin and estrogen were within normal range for her age. Total testosterone and free testosterone was normal. Her ultrasonography abdomen, transvaginal ultrasound, magnetic resonance imaging brain, computed tomography scan brain did not reveal any abnormality. Our patient was preoccupied with her increased sexual sensations and had feelings of guilt, shame, hopelessness, worthlessness. After workup, she was diagnosed conceptually to be a case of PGAD with depression. She was started on clomipramine 150 mg/day and clonazepam 1.5 mg/day in divided doses. After 2 weeks as we could not hike the dose of clomipramine due to giddiness, fluoxetine 40 mg/day was added and lignocaine gel local application was made 5−6 times a day along with pelvic floor exercises. She reported a marginal decrease in genital sensations as compared to before but was fluctuating. So after consultation with a gynecologist injection leuprolide3.75 mg (antiandrogen) subcutaneous was added to her treatment and advised to be repeated at 1 month interval for 3 months. Few days after 1st leuprolide injection, she reported a decrease in sexual sensation. The patient continued to improve and her genital sexual sensation significantly subsided at the time of discharge. She has received the 2nd and 3rd dose of injection leuprolide on follow-up and continued other medications as such. The patient is maintaining well for over 1½ years now.
A patient of PGAD is generally diagnosed as sexual dysfunction not otherwise specified in the official classificatory system. Similar cases of PGAD have been reported by Goldmeier and Leiblum and Korda et al. This is predominantly a female syndrome. However cases have been described in males. The symptoms of PGAD can be very distressing and debilitating, preventing concentration on daily tasks. Women with PGAD commonly report feelings of distress, frustration and guilt and frequently experience anxiety, panic attacks, and depression. There are limited data available for the management of PGAD. These include medications like antidepressants, varenicline, anesthetizing gels, electro-convulsive therapy if co-morbid with mood symptoms, transcutaneous electrical nerve stimulation, and cognitive behavioral therapy. No single treatment can be recommended for PGAD. Our patient responded marginally to antidepressants-clomipramine and fluoxetine along with local application of anesthetic lignocaine gel and pelvic floor exercises. The improvement was significantly enhanced by adding injection leuprolide and this may be related to endocrinal and neurological theory of PGAD. Leuprolide acts as an agonist at pituitary gonadotropin-releasing hormone receptors. It indirectly downregulates the secretion of gonadotropins-luteinizing hormone and FSH leading to hypogonadism.
The concept of PGAD is emerging in the literature. Few data are available for the management of the same. Here, we illustrate this rare variety of sexual dysfunction as PGAD and highlight the use of clomipramine, fluoxetine, lignocaine gel with pelvic floor exercises for the treatment of PGAD, emphasizing on the use of injection leuprolide in combination with the above.
We would thank Professor and Head Department of Psychiatry, Assam Medical College, Dr. H. K. Goswami for his valuable guidance.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
|1||Giraldi A, Graziottin A. Sexual arousal disorders in women. In: Porst H, Buvat J, editors. International Society of Sexual Medicine Standard Committee Book Standard Practice in Sexual Medicine. Oxford: Blackwell; 2006. p. 325-33.|
|2||Leiblum SR, Nathan SG. Persistent sexual arousal syndrome: A newly discovered pattern of female sexuality. J Sex Marital Ther 2001;27:365-80.|
|3||Goldmeier D, Leiblum S. Interaction of organic and psychological factors in persistent genital arousal disorder in women: A report of six cases. Int J STD AIDS 2008;19:488-90.|
|4||Korda JB, Pfaus JG, Kellner CH, Goldstein I. Persistent genital arousal disorder (PGAD): Case report of long-term symptomatic management with electroconvulsive therapy. J Sex Med 2009;6:2901-9.|
|5||Waldinger MD, Venema PL, van Gils AP, de Lint GJ, Schweitzer DH. Stronger evidence for small fiber sensory neuropathy in restless genital syndrome: Two case reports in males. J Sex Med 2011;8:325-30.|
|6||Leiblum SR. Arousal disorders in women: Complaints and complexities. Med J Aust 2003;178:638-40.|
|7||Korda JB, Pfaus JG, Goldstein I. Persistent genital arousal disorder: A case report in a woman with lifelong PGAD where serendipitous administration of varenicline tartrate resulted in symptomatic improvement. J Sex Med 2009;6:1479-86.|
|8||Hiller J, Heskster B. Couple's therapy with cognitive behavioural techniques for PSAS. Sex Relationsh Ther 2007;22:91-6.|
|9||Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J Sex Med 2010;7:586-614.|